Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

@article{Harvey1999EstrogenRS,
  title={Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.},
  author={J. Harvey and G. Clark and C. Osborne and D. Allred},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1999},
  volume={17 5},
  pages={
          1474-81
        }
}
  • J. Harvey, G. Clark, +1 author D. Allred
  • Published 1999
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose of this study was to evaluate the ability of ER status determination by IHC, compared with LBA, to predict clinical outcome-especially response to adjuvant endocrine therapy-in a large number of patients with long-term clinical follow-up… Expand

Paper Mentions

Interventional Clinical Trial
This is a single-arm, unicentric, single-stage clinical study of tamoxifen for patients with well differentiated neuroendocrine tumors and radiological progression with positive (> 1… Expand
ConditionsEstrogen Receptor Positive Tumor, Neuroendocrine Tumors, Progesterone Receptor Positive Tumor
InterventionDrug
Interventional Clinical Trial
Background: Identification of new biomarkers with potential predictive and prognostic role has contributed unequivocally to breast cancer treatment. Although traditionally… Expand
ConditionsBreast Cancer
InterventionDrug
Interventional Clinical Trial
This study will assess the usefulness of a technique called complementary deoxyribonucleic acid (cDNA) microarray-an examination of a wide array of genes to identify disease-associated… Expand
ConditionsBreast Cancer, Breast Neoplasm
InterventionDrug
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
  • M. Cheang, D. Treaba, +9 authors A. Gown
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 62 REFERENCES
...
1
2
3
4
5
...